Electric Field Therapy Shown to Prolong Survival in Pancreatic Cancer

Stopping Tumor Cells with Electricity — TTFields Technology and PANOVA-3

Cancer treatment has seen many innovations over the past 20 years. Yet in challenging conditions such as unresectable, locally advanced pancreatic cancer , treatment options that significantly prolong survival remain limited. A different, biophysics-based approach is now emerging alongside conventional chemotherapy and immunotherapy: Tumor Treating Fields (TTFields).

What Are TTFields, and Who Developed Them?

TTFields technology is a treatment method that uses alternating electric fields to prevent cancer cells from dividing while causing minimal damage to healthy tissue. This innovative approach was developed by Israeli professor of physiology and biophysics Yoram Palti and commercialized by the company founded in 2000, Novocure . The company is headquartered in Root, Switzerland.

FDA-Approved Uses of TTFields

The effectiveness of this technology has not remained merely theoretical: over the past 15 years, it has received approval for four different types of cancer from the US Food and Drug Administration (FDA) :

1. 2011 – Recurrent glioblastoma multiforme (a brain tumor) 📄 Read the detailed article
2. 2015 – Newly diagnosed glioblastoma in combination with chemotherapy 📄 Read the detailed article
3. 2019 – Mesothelioma (cancer of the lung lining) 📄 Read the detailed article
4. 2024 – Advanced non-small cell lung cancer 📄 Read the detailed article

These approvals show that TTFields is no longer simply an experimental method but has become a treatment platform whose effectiveness has been demonstrated in numerous randomized studies.

How Does the Device Work? Who Can Use It?

• Portable electrodes individually planned for each patientare placed over the anatomical region containing the tumor.
• The device is worn for an average of 18 hours a day and is rented to the patient.
• The cost of use in the US is 27,000 dollars per month, compared with approximately 20,000 euros in Europe.
• It is not yet available in Turkey.

The device technology has improved substantially over the past 15 years, becoming lighter, portable, and more patient-friendly. TTFields devices are now small enough to fit into a backpack and suitable for mobile use.

How was this technology tested in pancreatic cancer, and what were the results? Let us look at the PANOVA-3 study.

The PANOVA-3 Study: 75% Survival at 1 Year in Locally Advanced Pancreatic Cancer

At diagnosis, pancreatic cancer patients present in approximately the following proportions:

• 30%: The tumor is regionally advanced (locally advanced) and cannot be surgically removed (unresectable).
• 50%: Present at diagnosis with metastatic (stage 4) disease.
• Only 20%: Have operable (resectable) disease.

For patients with locally advanced pancreatic cancer, current treatment options have limited effectiveness. Median survival generally does not exceed a year, while the devastating effects on pain and quality of life further complicate patient care.

A development that could change this situation emerged from a study presented at the ASCO 2025 Congress and simultaneously published in the Journal of Clinical Oncology: the phase 3 PANOVA-3 study . It showed that Tumor Treating Fields (TTFields) technology, when combined with standard chemotherapy, significantly prolonged survival.

Study Summary

PANOVA-3 studied previously untreated patients with unresectable locally advanced pancreatic adenocarcinoma , enrolling 571 patients in a multicenter, randomized, phase 3 trial.

The two treatment arms compared were:

• Control group: Gemcitabine + nab-paclitaxel
• Experimental group: The same chemotherapy plus a TTFields device used for 18 hours a day .

📍 Median follow-up: 13.5 months (TTFields group), 12.9 months (control)

PANOVA-3 in Numbers: Improvements in Survival and Quality of Life

🟢 Median Overall Survival (mOS):

• All patients:
  • TTFields arm: 16.2 months
  • Control arm: 14.2 months 🔹 HR: 0.82 | p = 0.039

• Patients who actually received treatment:
  • TTFields arm: 18.3 months
  • Control arm: 15.1 months 🔹 HR: 0.77 | p = 0.023

💠 1-Year Survival Rate:

• TTFields: 75.1%
• Control: 65.9%

🔵 Pain-Free Survival:

• TTFields: 15.2 months
• Control: 9.1 months 🔹 HR: 0.74 | p = 0.027

🧩 Time to Deterioration:

• TTFields: 7.1 months
• Control: 5.7 months 🔹 HR: 0.77 | p = 0.023

What Are TTFields? How Do They Work?

TTFields deliver low-intensity alternating electric fields to the tumor region through electrodes, disrupting cancer cell division during mitosis and thereby preventing proliferation.

PANOVA-3 shows that this technology may also be effective in challenging tumors such as pancreatic cancer and is the first large-scale phase 3 study to do so.

Side Effect Profile: Manageable but Requires Monitoring

Adverse events were common in both arms:

• Grade ≥3 adverse events:
  • TTFields: 88.7%
  • Control: 84.2%
• Skin toxicities (prominent only in the TTFields arm):
  • Dermatitis: 29.9%
  • Itching: 22.3%
  • Rash: 25.9%

These adverse effects are generally manageable local skin reactions associated with device use.

Conclusion: A Paradigm Shift in Pancreatic Cancer?

PANOVA-3shows that the combination of TTFields and chemotherapy significantly improves not only survival but also pain management and quality of life. These findings could represent an important milestone for clinicians seeking to move beyond standard treatment options.

📣 Particularly in patients who can adhere well to device use, this combination could emerge as a new standard of care .

Key Points at a Glance

• ✅ Median overall survival: Up to +4 monthslonger (in patients able to use the device fully)
• ✅ In 1-year survival, a 10% increase
• ✅ Significantly longer pain-free survival
• ✅ An electromechanical, low-toxicity, non-systemic add-on treatment
• ✅ The first phase 3 success for TTFields in pancreatic cancer